Article Text

other Versions

Download PDFPDF
Randomised controlled trial
Antithrombotic therapy for pregnancy complications: let's not throw the baby out with the bath water
  1. Ian A Greer
  1. Faculty of Health & Life Sciences, University of Liverpool, Liverpool, UK
  1. Correspondence to: Prof. Ian A Greer, Faculty of Health & Life Sciences, University of Liverpool, Foundation Building, 765 Brownlow Hill, Liverpool L69 7ZX, UK; iag{at}liverpool.ac.uk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science

Context

Placenta-mediated pregnancy complications, ranging from miscarriage to growth restriction and pre-eclampsia, collectively affect more than 25% of pregnancies. While the aetiology of pregnancy complications is heterogeneous, it is plausible that common processes such as inflammation and activation of the coagulation system play key roles. Therefore, antithrombotic treatments, specifically low-dose aspirin (LDA) and low molecular-weight heparin (LMWH), have been used for these conditions, usually following the diagnosis of pregnancy. There are biological data indicating that LDA can improve endometrial growth and vascularisation in women undergoing assisted conception, suggesting that treatment-initiated preconception could influence pregnancy outcomes. There is limited information on preconceptional use of such agents. The Effects of Aspirin in Gestation and Reproduction (EAGeR) study examined the effects on live birth …

View Full Text

Footnotes

  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.